Akari Therapeutics Plc financial data

Symbol
AKTX on Nasdaq
Location
Tampa, FL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 17% % -32%
Debt-to-equity 114% %
Return On Equity -68% % -112%
Return On Assets -32% % 96%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71,479,461,523 shares
Common Stock, Shares, Outstanding 65,229,461,523 shares 169%
Entity Public Float $14,000,000 USD 2.9%
Common Stock, Value, Issued $6,523,000 USD 168%
Weighted Average Number of Shares Outstanding, Basic 65,326,236,698 shares 168%
Weighted Average Number of Shares Outstanding, Diluted 65,326,236,698 shares 168%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD
Research and Development Expense $2,976,000 USD -68%
General and Administrative Expense $1,281,985 USD -44%
Operating Income (Loss) $19,326,000 USD 17%
Nonoperating Income (Expense) $2,466,000 USD -52%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $7,488,000 USD -159%
Income Tax Expense (Benefit) $1,088,000 USD
Net Income (Loss) Attributable to Parent $15,772,000 USD 22%
Earnings Per Share, Basic 0 USD/shares -100%
Earnings Per Share, Diluted 0 USD/shares -100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $2,711,000 USD 1050%
Other Assets, Current $53,000 USD -42%
Assets, Current $2,946,000 USD 7.8%
Property, Plant and Equipment, Net $31,807 USD
Goodwill $8,430,000 USD
Other Assets, Noncurrent $11,136 USD
Assets $45,376,000 USD 1560%
Accounts Payable, Current $10,844,000 USD 127%
Accrued Liabilities, Current $1,623,000 USD -38%
Liabilities, Current $15,568,000 USD 65%
Deferred Income Tax Liabilities, Net $6,952,000 USD
Other Liabilities, Noncurrent $69,000 USD
Liabilities $22,689,000 USD
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,144,000 USD -24%
Retained Earnings (Accumulated Deficit) $259,252,000 USD -6.5%
Stockholders' Equity Attributable to Parent $22,687,000 USD
Liabilities and Equity $45,376,000 USD 1560%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,150,000 USD 47%
Net Cash Provided by (Used in) Financing Activities $2,133,000 USD 41%
Common Stock, Shares Authorized 330,854,276,210 shares 633%
Common Stock, Shares, Issued 65,229,461,523 shares 169%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $17,000 USD 99%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2,544,000 USD 13%
Interest Paid, Excluding Capitalized Interest, Operating Activities $7,000 USD
Deferred Tax Assets, Valuation Allowance $60,340,000 USD 43%
Deferred Tax Assets, Gross $60,436,000 USD 34%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $15,990,000 USD 13%
Operating Lease, Liability, Current $4,603,516 USD
Deferred Tax Assets, Operating Loss Carryforwards $56,704,000 USD 32%
Preferred Stock, Shares Authorized 10,000,000 shares
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $224,366,000 USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $13,000 USD 1200%
Deferred Tax Assets, Net of Valuation Allowance $96,000 USD -97%
Share-based Payment Arrangement, Expense $3,675,000 USD 156%
Interest Expense $100,000 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares